分子量: 2522.882 Da / 分子数: 1 / 断片: N-TERMINAL DOMAIN(RESIDUE 132-152) / 由来タイプ: 合成 / 詳細: This sequence occurs naturally in humans. / 参照: UniProt: P18509
-
実験情報
-
実験
実験
手法: 溶液NMR
NMR実験
Conditions-ID
Experiment-ID
Solution-ID
タイプ
1
1
1
TRNOESY
2
2
1
TRNOESY
NMR実験の詳細
Text: Both TRNOE and NOE cross peaks were observed in the spectrum: the former reflects the conformation of PACAP21 in the receptor-bound form, while the latter reflects that of unbound PACAP21. Upon ...Text: Both TRNOE and NOE cross peaks were observed in the spectrum: the former reflects the conformation of PACAP21 in the receptor-bound form, while the latter reflects that of unbound PACAP21. Upon addition of a higher affinity ligand, PACAP27, the TRNOE cross peaks were selectively eliminated due to a competitive inhibition of the specific binding of PACAP21 to the receptor. Accordingly, the subtraction of these two spectra yields TRNOE-related cross peaks exclusively.
タイプ: Bruker DRX / 製造業者: Bruker / モデル: DRX / 磁場強度: 800 MHz
-
解析
NMR software
名称
バージョン
開発者
分類
X-PLOR
3.1
Brunger, A.T.
構造決定
IRMA
30-Jul-90
Kaptein, R.
iterativematrixrelaxation
X-PLOR
3.1
Brunger, A.T.
精密化
精密化
手法: Iterative relaxation matrix analysis (IRMA), simulated annealing (SA) ソフトェア番号: 1 詳細: The structures are calculated by SA protocol of X-PLOR based on a total of 387 TRNOE-derived distance restraints obtained from the IRMA refinement.
代表構造
選択基準: closest to the average
NMRアンサンブル
コンフォーマー選択の基準: structures with the lowest energy 計算したコンフォーマーの数: 200 / 登録したコンフォーマーの数: 25